April 2024 Newsletter
Welcome to the monthly Crown Bioscience newsletter. Discover some of our monthly highlights to keep up to date with recent developments and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!
Have you seen the latest preclinical and translational drug development data from the 2024 AACR Annual Meeting?
Our ten new posters are available to view online and you can schedule a time to discuss any poster with one of our experts at your convenience.
Our cutting-edge cell-free plasma biobank offers frozen longitudinal Streck plasma from over 20,000 cancer patients, meticulously preserved in 1 mL barcoded cryotubes .
Our collection not only encompasses a wide spectrum of cancer types and therapies, including immune modulators, but is also complemented by extensive clinical data and patient consent for targeted genomic analysis.?
Join our upcoming webinar on 'Four-Step Preclinical Strategy to Tackle Cancer Drug Resistance ' on April 25, 2024, to explore innovative strategies for overcoming the challenges of drug resistance in cancer therapy.
You will have the opportunity to learn how an integrated approach can transform early drug discovery and combat this critical barrier to successful cancer treatment.
SynAI, a state-of-the-art AI-driven solution poised to redefine the approach to predicting drug synergism in cancer cell lines.
SynAI offers a swift, efficient, and cost-effective method for identifying promising therapeutic combinations . It signifies a leap towards a more dynamic and scalable drug discovery process, unshackled from the limitations of traditional screening methods.
Novel murine immunocompetent models are needed to overcome issues with commonly used syngeneic tumor models , genetically engineered mouse models (GEMM), and somatically engineered mouse models (SEMM).
Read our blog post to learn advantages and limitations of syngeneic models, GEMM, SEMM, and novel tumor homograft models.
Pretreated PDX models derived from patients receiving modern therapies can be used to address drug resistance and develop innovative anticancer therapies .
Our white paper includes three case studies on the establishment and validation of pretreated PDX models (colorectal cancer, prostate cancer, and breast cancer).
Learn how to address the high attrition rate in oncology drug development with our study showcasing a large-scale proof-of-concept organoid experiment .
This research leverages next-generation sequencing to dissect the drug's mechanism of action and unearth biomarkers predicting drug responses.
? 2024 Crown Bioscience
Crown Bioscience, Inc. 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States